These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 32559715)

  • 1. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
    Lin H; Zhang R; Wu W; Lei L
    Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Analysis of the Sorafenib-Associated Druggable Targets on Differential Gene Expression and ceRNA Network in Hepatocellular Carcinoma.
    Fu Z; Yang G; Wang T; Gao D; Lin D; Liu X
    J Environ Pathol Toxicol Oncol; 2023; 42(4):47-60. PubMed ID: 37522567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
    Jiang X; Zhang W; Li L; Xie S
    Pathol Oncol Res; 2021; 27():1609985. PubMed ID: 34737677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative analysis of the molecular signature of target genes involved in the antitumor effects of cantharidin on hepatocellular carcinoma.
    Yan J; Gao YM; Deng XL; Wang HS; Shi GT
    BMC Cancer; 2023 Nov; 23(1):1161. PubMed ID: 38017425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
    Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
    Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
    Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
    Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of aberrantly expressed lncRNA and the associated TF-mRNA network in hepatocellular carcinoma.
    Wang B; Tang D; Zhang Z; Wang Z
    J Cell Biochem; 2020 Feb; 121(2):1491-1503. PubMed ID: 31498488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence.
    Yan P; Huang Z; Mou T; Luo Y; Liu Y; Zhou B; Cao Z; Wu Z
    BMC Cancer; 2021 Apr; 21(1):436. PubMed ID: 33879119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioinformatics analysis revealed hub genes and pathways involved in sorafenib resistance in hepatocellular carcinoma.
    Liu J; Qiu WC; Shen XY; Sun GC
    Math Biosci Eng; 2019 Jul; 16(6):6319-6334. PubMed ID: 31698564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines.
    Zhang Z; He CZ; Qin YQ; Liao JJ; Huang ST; Mo S; Li HM; Lin JY
    Aging (Albany NY); 2020 Nov; 12(23):24255-24269. PubMed ID: 33234725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic regulation of DNA repair gene program by Hippo/YAP1-TET1 axis mediates sorafenib resistance in HCC.
    Mo C; You W; Rao Y; Lin Z; Wang S; He T; Shen H; Li X; Zhang R; Li B
    Cell Mol Life Sci; 2024 Jul; 81(1):284. PubMed ID: 38967794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma.
    Yoo JJ; Yu SJ; Na J; Kim K; Cho YY; Lee YB; Cho EJ; Lee JH; Kim YJ; Youn H; Yoon JH
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
    Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
    Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance.
    Xia S; Ji L; Tao L; Pan Y; Lin Z; Wan Z; Pan H; Zhao J; Cai L; Xu J; Cai X
    Cell Mol Gastroenterol Hepatol; 2021; 12(3):1121-1143. PubMed ID: 33962073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
    Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
    Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.
    Lou W; Liu J; Ding B; Chen D; Xu L; Ding J; Jiang D; Zhou L; Zheng S; Fan W
    J Transl Med; 2019 Jan; 17(1):7. PubMed ID: 30602391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of core genes and outcomes in hepatocellular carcinoma by bioinformatics analysis.
    Shen S; Kong J; Qiu Y; Yang X; Wang W; Yan L
    J Cell Biochem; 2019 Jun; 120(6):10069-10081. PubMed ID: 30525236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
    Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
    Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.